XORTX Therapeutics Inc. (XRTX)
XORTX Therapeutics Inc.
3710 – 33rd Street NW
Alberta Beach, AB T2L 2M1
Canada
(403) 455-7727
https://www.xortx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 2
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Allen Warren Davidoff Ph.D. | Founder, CEO, President & Director | 358.43k | N/D | 1960 |
| Mr. James Neville Fairbairn C.A., C.P.A., ICD.D | Interim Chief Financial Officer | 42.76k | N/D | 1963 |
| Dr. Stephen Haworth M.D., MRCP | Chief Medical Officer | 228.35k | N/D | 1950 |
| Dr. Stacy Evans M.B.A., M.D. | Chief Business Officer | 84.53k | N/D | 1974 |
| Nick Rigopoulos | Director of Communications | N/D | N/D | N/D |
| Dr. David Sans M.B.A., Ph.D. | Director of Corporate Development | N/D | N/D | 1970 |
| Dr. David MacDonald Ph.D. | Consultant of Clinical Operations | N/D | N/D | 1964 |
| Ms. Charlotte May | Corporate Secretary | N/D | N/D | N/D |
Descripción
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada.
Gestión corporativa
La calificación ISS Governance QuickScore de XORTX Therapeutics Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
